eligibility_summary
Inclusion: Adults (≥18) with untreated ES‑SCLC, measurable disease, tissue/blood available, ECOG 0–1, life ≥12 wks, contraception, non‑pregnant. Exclusion: prior B7‑H3, recent RT/surgery or effusions, CYP3A4/QT‑risk meds, active CNS/spinal mets or fistula risk, unresolved >G2 toxicity, organ dysfunction/poor marrow, CV, lung, liver (Child‑Pugh B+), or neuropsychiatric disease, uncontrolled DM/HTN, recent bleeding/thrombosis, immunodeficiency/transplant or chronic steroids, active infections, HS‑20093 allergy, noncompliance
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
ARTEMIS-007 (NCT06052423) is a withdrawn Phase 2, single-arm study of HS-20093 in extensive-stage small cell lung cancer. Intervention: HS-20093, a fully humanized IgG1 antibody-drug conjugate (ADC), 10 mg/kg IV every 3 weeks. Mechanism: HS-20093 specifically binds B7-H3 (CD276) on tumor cells, is internalized, and releases a cytotoxic payload to induce targeted tumor cell death (ADC-mediated delivery). Targets: B7-H3–expressing SCLC cells, pathway focus is the B7 family (B7-H3 immune checkpoint axis) associated with tumor immune evasion and overexpression on solid tumors.